Therapeutic Purpose

Axid (nizatidine) is a histamine H2-receptor antagonist used to manage conditions characterized by excessive gastric acid production. By blocking histamine receptors in the stomach lining, the medication reduces the volume and acidity of gastric secretions, which facilitates the healing of damaged tissues and provides relief from acid-related symptoms.

Primary Indications

Gastric and Duodenal Ulcers

The medication is used for the treatment of active duodenal ulcers and active benign gastric ulcers. Beyond initial treatment, it is also utilized for maintenance therapy at reduced dosages to prevent the recurrence of duodenal ulcers after the initial lesions have healed.

Gastroesophageal Reflux Disease (GERD)

Axid is indicated for the treatment of endoscopically diagnosed esophagitis and associated symptoms such as heartburn caused by gastroesophageal reflux disease. It helps manage the inflammation of the esophageal lining resulting from the backward flow of stomach acid.

Benefits and Clinical Effects

• Acid Reduction: The primary benefit of the medication is its ability to significantly decrease both basal and stimulated gastric acid secretion.
• Symptom Management: It provides effective relief from common symptoms associated with hyperacidity, including persistent heartburn and acid indigestion.
• Tissue Healing: By creating a less acidic environment, the medication supports the natural healing process of the mucosal lining in the stomach and esophagus.
• Prevention: When used as a maintenance treatment, it helps reduce the clinical frequency of ulcer recurrence in chronic patients.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Аксид (Nizatidine) — Official Regulatory Information

Contraindications (Must Not Use)

Nizatidine is strictly contraindicated for any patient with a documented history of hypersensitivity or allergic reaction to nizatidine itself. It is also contraindicated for individuals with a known hypersensitivity to any other H2-receptor antagonists (the drug class to which it belongs), as cross-sensitivity has been observed.

Restricted Use and Special Considerations

• Kidney Impairment: Patients with moderate to severe renal impairment must use this medicine with caution. Since nizatidine is primarily excreted by the kidneys, the dosage must be reduced in proportion to the severity of the dysfunction to prevent the drug from accumulating in the body.
• Liver Function: Caution is also warranted for patients with hepatic impairment (liver dysfunction).
• Children and Adolescents: Non-prescription use is indicated for adults and children 12 years of age and older. The safety and effectiveness for use in children under 12 years of age have not been fully established and must be determined by a healthcare professional.
• Gastric Conditions: Before starting treatment for benign gastric ulcer, a medical professional must exclude the possibility of a gastric malignancy (stomach cancer), as the medicine’s symptom relief could mask a serious underlying condition.

Patients should inform their healthcare provider about any kidney or liver conditions, any known drug allergies, and if they are pregnant or breastfeeding, as these factors may affect eligibility or require dose adjustment.

Interactions with other medicines and products

The interaction profile of Аксид (Nizatidine) is defined primarily by its effect on gastric pH and its specific profile regarding metabolic enzymes, as documented in regulatory sources.

Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system, meaning that pharmacokinetic interactions mediated by the inhibition of hepatic metabolism are not expected to occur.

Clinically Significant Exposure Modification

The primary interaction mechanism involves the reduction of exposure for co-administered medicinal products that require an acidic gastric pH for dissolution and absorption. This may significantly decrease the levels of agents such as Acalabrutinib, Bosutinib, Dasatinib, Defactinib, Itraconazole, and Ketoconazole.

Interacting Product	Restriction or Required Separation
Acalabrutinib (Capsules)	Administer 2 hours prior to Nizatidine.
Bosutinib	Administer more than 2 hours before or after Nizatidine.
Defactinib	Administer at least 2 hours apart.

Other Documented Interactions

Concomitant use of Nizatidine with very high doses of salicylates (e.g., 3,900 mg/day Aspirin) may result in an increase in serum salicylate levels. Additionally, co-administration with aluminum and magnesium antacids slightly decreases Nizatidine's own bioavailability by approximately 10%. Food intake results in a slight increase in Nizatidine's absorption.

Population-Specific Interaction Notes

Patients with moderate to severe renal impairment may experience increased exposure to Nizatidine due to reduced renal clearance, which is a key interaction-related consideration.

How Аксид Works (Mechanism of Action)

Targeting the H2 Receptor Pathway

Axid (Nizatidine) exerts its action as a selective H2 receptor antagonist, directly binding to and occupying these receptors on the basolateral membrane of gastric parietal cells. This interaction is competitive and effectively interrupts the normal signaling sequence where histamine stimulates acid production, making the drug relevant in systems where this specific H2-mediated signaling pathway dominates.

Modulation of Gastric Secretion Cascades

By blocking the H2 receptor, Axid modifies the early molecular steps that govern acid production. This action reduces the intensity of the intracellular signaling cascade (specifically, preventing the rise in cyclic AMP), which limits the activation of signaling sequences by influencing the H^+ / K^+-ATPase (proton pump), the final effector enzyme.

Physiological Adjustment of Acid Homeostasis

The resulting physiological effect of the receptor blockade and cascade interference is a reduction in both the volume and hydrogen ion concentration (acidity) of gastric fluid. This mechanistic domain modifies the acidic environment within the stomach, leading to consistent physiological adjustments that shape the drug's overall pharmacological effect profile.

How to Use Аксид (Nizatidine)

The usage of Аксид is defined by specific administration routes, standardized dosing schedules, and duration patterns. The medication's primary route of administration is oral, available in various forms including capsules, tablets (prescription 150 mg, 300 mg; and over-the-counter 75 mg), and oral solution.

---

Standard Dosing and Frequency

Prescribed regimens typically utilize a once-daily (qHS) or twice-daily (bid) schedule. For acute conditions, the standard dose is often 300 mg taken once daily at bedtime, or alternatively, 150 mg taken twice daily. The dose used for long-term maintenance therapy of healed ulcers is generally 150 mg once daily at bedtime.

Treatment duration is classified into finite courses, such as up to 8 weeks for active duodenal ulcers or up to 12 weeks for erosive esophagitis. Maintenance therapy may be used for a maximum of one year at a reduced dose to prevent recurrence.

---

Administration Context and Adjustments

Аксид may be administered without regard to meals; however, the over-the-counter dose intended for heartburn prevention is taken 30 to 60 minutes before eating.

There is a requirement for dose adjustment in patients with renal impairment (Creatinine Clearance < 50 mL/min). In these cases, the dose is reduced or the dosing interval extended to ensure appropriate use. If a dose is missed, the standard practice is to skip the missed dose if it is almost time for the next scheduled dose, rather than doubling the dose.

Research Evidence / Overview of Studies for Аксид (Nizatidine)

The evidence base for Nizatidine centers on randomized controlled trials (RCTs) and comparative studies, which are a common type of clinical evaluation. These studies explored how the medicine was evaluated in conditions related to acid production in the stomach and digestive tract. Findings reported in the research describe patterns observed in specific, short-term treatment settings and provide context for its use, while also highlighting where research remains incomplete.

---

Evidence for Use in Healing Active Ulcers (Duodenal and Gastric)

Research on Duodenal Ulcer Maintenance

For active ulcers, most research involved short-term (4- to 8-week), placebo-controlled RCTs in adults with endoscopically confirmed duodenal or benign gastric ulcers. The main outcomes studied included the rate of achieving a pre-defined endoscopic ulcer resolution, which was verified by follow-up endoscopy. Research also examined secondary patient-reported outcomes, such as the change in reported pain intensity and measurements of antacid usage.

What remains uncertain: The research provides limited information for periods extending beyond 8 weeks for the acute healing phase. Furthermore, trials suggested that outcomes may be affected by factors like ulcer size and smoking habits, meaning results apply only to the populations studied. For gastric ulcers, research does not provide context for ulcers linked to malignancy, as standard protocol required confirming the ulcer was benign before starting treatment.

---

Evidence for Acid-Related Damage in the Esophagus (Erosive Esophagitis/GERD)

Studies that evaluated Nizatidine in the context of erosive esophagitis consisted primarily of short-term RCTs lasting up to 12 weeks. Researchers focused on objectively measuring the rate of achieving a pre-defined endoscopic change in the condition of erosions and ulcerations. Findings described the measurements of the pre-defined endoscopic change in the esophageal lining across the study intervals. Comparative evidence against other acid-suppressing medicines has been conducted, and these studies reported varying outcomes when measuring the pre-defined endpoints between the different treatments.

---

Long-Term Research and Durability of Outcomes

Research has explored the use of Nizatidine for duodenal ulcer maintenance, where the medicine was studied in the context of ulcer recurrence rate in patients whose ulcers had already healed. These studies monitored recurrence rates over intermediate time intervals, typically up to 12 months. Research highlights that long-term effects are not fully established, and follow-up durations were limited to one year in the main maintenance trials.

Key Studies & References

1. NIH/NLM DailyMed Drug Record: Nizatidine Capsules
2. NIH MedlinePlus Overview of Nizatidine (Acute Symptoms)

Common questions about Аксид (FAQ)

---

Q: Does taking Аксид affect the absorption of other medicines in my body?

According to the official product information, Аксид may potentially affect how some other medicines are absorbed. This is because Аксид can change the level of stomach acid, which is an important factor for the body's uptake of certain other drug products.

Q: Can I take antacids (like Tums) while I am using Аксид?

Official product information states that taking antacids at the same time as Аксид does not appear to affect the overall absorption of Аксид into the body. Regulatory information suggests that the combined use of antacids does not significantly alter the amount of Аксид absorbed by the body.

Q: Is Аксид effective for heartburn relief?

Regulatory documents state that Аксид is indicated for the treatment of heartburn, which is a common symptom of conditions like gastroesophageal reflux disease (GERD). Studies and official information indicate that it works by reducing the amount of acid produced by the stomach.

Q: What is the primary way Аксид works to treat stomach issues?

Studies and official information indicate that Аксид works by blocking certain chemical substances in the stomach lining known as histamine H2-receptors. By performing this block, Аксид reduces the production of stomach acid, which helps to heal ulcers and relieve acid-related pain.

Q: Can I use Аксид to treat stomach ulcers?

Regulatory documents state that Аксид is approved for the treatment of certain types of stomach ulcers, including duodenal ulcers and benign gastric ulcers. It helps to create a less acidic environment, which supports the healing process of these ulcers.

Q: What is the maximum amount of time I can take Аксид for?

According to official product information, the duration of use is determined by the specific condition being addressed. The length of time Аксид is taken may vary considerably, depending on whether it is being used for acute duodenal ulcers, erosive esophagitis, or other indications.

Q: Will Аксид prevent stomach bleeding from taking pain relievers like NSAIDs?

Official product information includes an indication for Аксид to reduce the risk of upper gastrointestinal bleeding in patients who are critically ill. This indication is generally specific to critically ill patients in a hospital setting and is not typically extended to routine use alongside common over-the-counter pain relievers.

Storage and Protection Requirements

Nizatidine capsules must be stored at Controlled Room Temperature to maintain the drug's labeled stability and quality. Official labeling requires storage between 20 C and 25 C (68 F and 77 F), though brief excursions are permitted up to 30 C (86 F). The product must be stored in a tight container and protected from excessive heat and moisture.

Constraint	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Protection	Keep tightly closed; Protect from excessive heat and moisture
Child Safety	Must be kept out of the reach of children

Official Disposal Instructions

For disposal of unused or expired Nizatidine capsules, patients must ask a healthcare professional or pharmacist for guidance. This ensures that the medication is discarded in a manner compliant with all applicable federal, state, and local regulations.